MX2022016223A - Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo. - Google Patents

Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo.

Info

Publication number
MX2022016223A
MX2022016223A MX2022016223A MX2022016223A MX2022016223A MX 2022016223 A MX2022016223 A MX 2022016223A MX 2022016223 A MX2022016223 A MX 2022016223A MX 2022016223 A MX2022016223 A MX 2022016223A MX 2022016223 A MX2022016223 A MX 2022016223A
Authority
MX
Mexico
Prior art keywords
tetrazol
ethyl
pharmaceutical compositions
ester derivatives
uorodecahydroisoquinoline
Prior art date
Application number
MX2022016223A
Other languages
English (en)
Inventor
James Philip Pearson
Eduardo Javier Martinez
Original Assignee
Sea Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sea Pharmaceuticals Llc filed Critical Sea Pharmaceuticals Llc
Publication of MX2022016223A publication Critical patent/MX2022016223A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se divulgan ácido 6-(2-(2H-tetrazol-5-il)etil)-6-fluorodecahidrois oquinolina-3-carboxílico y derivados de éster de hidrocarbilo de ácido 6-(2-(2H-tetrazol-5-il)etil)-6-fluorodecahidroisoquinolina-3 -carboxílico de la fórmula (ver Fórmula) como lo son las composiciones farmacéuticas y métodos para el tratamiento del dolor, epilepsia, convulsiones, y ataques empleando esas composiciones.
MX2022016223A 2020-07-02 2021-07-02 Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo. MX2022016223A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063047359P 2020-07-02 2020-07-02
PCT/US2021/040339 WO2022006537A1 (en) 2020-07-02 2021-07-02 Pharmaceutical compositions of 6-(2-(2h-tetrazol-5-yl)ethyl)-6-fluorodecahydroisoquinoline-3-carboxylic acid and ester derivatives thereof

Publications (1)

Publication Number Publication Date
MX2022016223A true MX2022016223A (es) 2023-02-23

Family

ID=79317835

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022016223A MX2022016223A (es) 2020-07-02 2021-07-02 Composiciones farmaceuticas de acido 6-(2-(2h-tetrazol-5-il)etil)- 6-fluorodecahidroisoquinolina-3-carboxilico y derivados de ester del mismo.

Country Status (9)

Country Link
US (1) US11685726B2 (es)
EP (1) EP4175635A4 (es)
JP (1) JP2023533387A (es)
KR (1) KR20230048003A (es)
AU (1) AU2021299570A1 (es)
CA (1) CA3187424A1 (es)
IL (1) IL299471A (es)
MX (1) MX2022016223A (es)
WO (1) WO2022006537A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023130008A2 (en) * 2022-01-01 2023-07-06 Sea Pharmaceuticals Llc Pharmaceutical compositions of 6-(2-(2h-tetrazol-5-yl)ethyl)decahydroisoquinoline-3-carboxylic acid and derivatives thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK704488D0 (da) * 1988-12-19 1988-12-19 Novo Industri As Nye n-substituerede azaheterocykliske carboxylsyrer
ATE100132T1 (de) 1987-09-19 1994-01-15 Hoechst Ag Fluessigkristalline, insbesondere ferroelektrische fluessigkristalline mischungen.
US5284957A (en) 1992-09-03 1994-02-08 Eli Lilly And Company Excitatory amino acid receptor antagonists
ATE240299T1 (de) 1999-07-06 2003-05-15 Lilly Co Eli Diester prodrugs von decahydroischinoline-3- carbonsäure
KR100757787B1 (ko) * 2002-04-26 2007-09-11 일라이 릴리 앤드 캄파니 진통제로서의 데카히드로이소퀴놀린-3-카르복실산의 에스테르 유도체

Also Published As

Publication number Publication date
CA3187424A1 (en) 2022-01-06
EP4175635A1 (en) 2023-05-10
US20230150971A1 (en) 2023-05-18
KR20230048003A (ko) 2023-04-10
EP4175635A4 (en) 2024-06-26
WO2022006537A1 (en) 2022-01-06
JP2023533387A (ja) 2023-08-02
AU2021299570A1 (en) 2023-02-23
IL299471A (en) 2023-02-01
US11685726B2 (en) 2023-06-27

Similar Documents

Publication Publication Date Title
MX2018012711A (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
MA37405A1 (fr) Composés hétérocyclyle
PH12020550881A1 (en) Substituted bicyclic heterocyclic compounds as prmt5 inhibitors
IN2012DN03085A (es)
WO2011027249A3 (en) Benzimidazole derivatives
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
WO2012054721A8 (en) Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors
SG10201407453TA (en) Kinase inhibitors
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
WO2014106800A8 (en) Substituted 2-amino pyrimidine derivatives as kinase inhibitors
NZ596228A (en) Compositions and methods for the treatment of inflammation
BR112012014486A2 (pt) derivados de aril triazol heteroaromático como inibidaores de enzima pde10a
EA201290516A1 (ru) Гетероароматические производные соединения фенилимидазола в качестве ингибиторов фермента pde10a
EA201492127A1 (ru) Пролекарственные производные (е)-n-метил-n-((3-метилбензофуран-2-ил)метил)-3-(7-оксо-5,6,7,8-тетрагидро-1,8-нафтиридин-3-ил)акриламида
WO2010124121A8 (en) Heteroaromatic and aromatic piperazinyl azetidinyl amides as monoacylglycerol lipase inhibitor
MX2009011753A (es) Inhibidores de enzima de diacilglicerol o-aciltransferasa tipo 1.
MA35411B1 (fr) Nouvelle composition thérapeutique contenant de l'apomorphine comme principe actif
MX2011009709A (es) Compuestos para el tratamiento de la inflamacion y del dolor.
MX2018014164A (es) Intermedios para la sintesis de derivados de acido biliar, en particular, de acido obeticolico.
MX2019010096A (es) Derivados de 1, 4, 6-trisustituidos-2-alquil-1h-benzo[d]imidazol como inhibidores de dihidroorotato oxigenasa.
MY165902A (en) Substituted pyridine derivatives as fabi inhibitors
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
PH12019500497A1 (en) Heteroaryl carboxamide compounds as inhibitors of ripk2
MX2012015100A (es) Compuestos y composiciones de heteroarilo como inhibidores de cinasa de proteina.
MX2022000083A (es) Inhibidores de monoacilglicerol lipasa (magl) heterociclicos.